Chimeric Antigen Receptor transduced T Cell based Artificial T Cell Stimulator Development Service

Online Inquiry

The Significance of Artificial T Cell Stimulator Development for CAR-T Cell Improving

Chimeric antigen receptor T cell (CAR-T) therapy has emerged as a major treatment for aggressive B cell tumors, with potential for additional malignancies. However, its high production costs, which are caused by single-use reagents for T cell activation and clinical-grade viral vectors, prevent its widespread application. The development of a cell-based artificial T cell stimulator that allows for continuous T cell stimulation might provide a cost-effective and efficient alternative to CAR-T cell activation, thereby reducing production costs and broadening access to this therapy.

Artificial T Cell Stimulator for CAR-T Cell Therapy Enhancement

Improved T cell activation

Artificial T cell stimulators can more closely mimic the natural interactions between T cells and antigen-presenting cells (like dendritic cells), leading to a more physiological and potentially more effective T cell activation.

Reduced manufacturing costs

Enhanced T cell function

Studies suggest that artificial T cell stimulators-activated CAR T cells may exhibit improved characteristics, such as increased potency and persistence in the body.

Fig.1 Schematic illustration of T cell receptor (TCR) and chimeric antigen receptor (CAR) structures, as well as mechanism of CAR T cell treatment. Fig.1 The structure of TCR and CAR as well as CAR-T cell therapy mechanism.^1,3

Chimeric Antigen Receptor Transduced T Cell based Artificial T Cell Stimulator Development Service at Creative Biolabs

Creative Biolabs globally delivers a cost-effective chimeric antigen receptor transduced T cell based artificial T cell stimulator development service, aiming to improve CAR-T cell immunotherapy and broaden its application. Our offerings encompass the totality of the process, ranging from the construction of the artificial T cell stimulator, and the optimization of the artificial T cell stimulator to the functional characterization of artificial T cell stimulator and activated CAR-T cells. With cutting-edge cell engineering technologies and stringent quality assurance protocols in place, we are capable of swiftly and efficiently producing high-performance artificial T cell stimulators, enabling accurate activation and expansion of CAR-T cells.

Furthermore, we offer customized experimental design and data analysis services to meet the specific needs of each customer. We are dedicated to working hand in hand with our customers to advance CAR-T cell immunotherapy into clinical practice.

Featured Advantages

Integrated service process ranging from artificial T cell stimulator construction, and optimization to characterization.
Cutting-edge cell engineering technologies.
Stringent quality assurance.
Swift and efficient results delivery.
Individualized artificial T cell stimulator development design and implementation.

Published Data

Background: Autologous CD19 CAR T-cell treatments have been extremely effective in treating specific blood malignancies. However, their efficacy can be hampered by limited and uneven T-cell functioning, which varies greatly between patients. This heterogeneity is determined by factors such as the patient's underlying health status and the quality of the initial T-cell population.

Method: This study investigated the impact of a novel artificial T cell stimulator scaffold on CAR T-cell functionality. This innovative artificial T cell stimulator platform utilizes a physiological fluid bilayer to precisely deliver critical T-cell stimulatory ligands, namely anti-CD3 and anti-CD28, at well-defined densities. A diverse set of blood samples was collected, including those from healthy donors and patients with acute lymphoblastic leukemia (ALL) or chronic lymphocytic lymphoma (CLL), representing a spectrum of patient health status. These samples were then used to generate a library of CAR T-cell products using the artificial T cell stimulator scaffold.

Results: By employing this synthetic artificial T cell stimulator platform, the study successfully generated a library of CAR T-cell products from both healthy and patient blood samples (ALL and CLL). This platform, with its ability to precisely control the delivery of T-cell stimulatory signals, provides a valuable tool for investigating and potentially optimizing CAR T-cell production and function across diverse patient populations.

Fig.2 Stimulation strength and quality during T-cell activation drives the production of distinct CAR-T cell products. Fig.2 The quality and potency of generated CAR-T cells are directly determined by the strength and nature of the signals received during their activation.^2,3

Associated Services

Creative Biolabs offers a wide range of specialized artificial T cell stimulator development services, not just for CAR-T cells but also for other immune cell types. Our services include the customization of artificial T cell stimulators for CD4+ T cells, CD8+ T cells, CD3+ T cells, NK cells, and others. This comprehensive range expands our capabilities to assist a wide range of immunological research and therapeutic applications, ensuring that we satisfy the needs of our customers' individual demands in progressing their projects.

For further information, please follow the link to contact us about creating a customized, flexible artificial T cell stimulator for CAR-transduced T cell stimulation.

References

Aggeletopoulou, Ioanna, Maria Kalafateli, and Christos Triantos. "Chimeric Antigen Receptor T Cell Therapy for Hepatocellular Carcinoma: Where Do We Stand?." International Journal of Molecular Sciences 25.5 (2024): 2631.
Zhang, David KY, et al. "Enhancing CAR-T cell functionality in a patient-specific manner." Nature Communications 14.1 (2023): 506.
Distributed under Open Access License CC BY 4.0, without modification.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.